Nazgol Bahreini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nazgol Bahreini has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bagher Larijani
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences
1 shared publication - Mehdi Karimi
Faculty of Medicine Bogomolets National Medical University (NMU) Kyiv Ukraine
1 shared publication - Niyousha Shirsalimi
Faculty of Medicine, Hamadan University of Medical Science (UMSHA), Hamadan, Iran
1 shared publication - Omid Asbaghi
Cancer Research Center Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publication - Samira Pirzad
Faculty of Medicine, Islamic Azad University, Tehran Medical Sciences Branch (IAUTMU), Tehran, Iran
1 shared publication - Seyed Morteza Ali Pourfaraji
Faculty of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
1 shared publication
Latest Publications
- 12 July 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 164
Propolis supplementation improves cardiometabolic health in patients with type 2 diabetes mellitus: findings from a GRADE-assessed systematic review and meta-analysis of RCTs
Diabetes is a common metabolic disorder associated with cardiometabolic complications. Propolis, a natural resinous compound, has shown potential benefits in improving metabolism. However, existing evidence remains inconsistent and fragmented. This study aims to systematically review and meta-analyze to evaluate the impact of propolis supplementation on cardiometabolic indices in patients with Type 2 diabetes mellitus (T2DM). A comprehensive search was performed in online major databases up to April 2025 to identify eligible randomized controlled trials (RCTs). Studies meeting the inclusion criteria were systematically reviewed and analyzed for relevant outcomes. A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs), taking into account study heterogeneity. The pooled analysis of 13 RCTs revealed that propolis supplementation in individuals with T2DM led to a significant reduction in fasting plasma glucose (WMD: -15.29 mg/dL), 2-hour postprandial glucose (WMD: -35.41 mg/dL), HbA1c (WMD= -0.58%), fasting insulin (WMD: -1.93 µU/mL), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (WMD: -0.99), low-density lipoprotein cholesterol (LDL-C) (WMD: -11.47 mg/dL), interleukin 6 (IL-6) (WMD: 1.52 pg/mL), tumor necrosis factor-alpha (TNF-α) (WMD: 2.28 pg/mL), and body weight (WMD: 2.09 kg). In contrast, the meta-analysis revealed no significant changes in triglycerides (TG) (p = 0.055), total cholesterol (TC) (p = 0.248), high-density lipoprotein cholesterol (HDL-C) (p = 0.068), and body mass index (BMI) (p = 0.204). Propolis supplementation may serve as a beneficial adjunct therapy for patients with T2DM, showing significant improvements in blood glycemic markers, serum lipid profile, inflammation, and body weight. The overall findings support the use of propolis as a promising complementary approach to enhance cardiometabolic health in T2DM. Not applicable. The online version contains supplementary material available at 10.1007/s40200-025-01682-w.
- 12 July 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 164
Propolis supplementation improves cardiometabolic health in patients with type 2 diabetes mellitus: findings from a GRADE-assessed systematic review and meta-analysis of RCTs
Diabetes is a common metabolic disorder associated with cardiometabolic complications. Propolis, a natural resinous compound, has shown potential benefits in improving metabolism. However, existing evidence remains inconsistent and fragmented. This study aims to systematically review and meta-analyze to evaluate the impact of propolis supplementation on cardiometabolic indices in patients with Type 2 diabetes mellitus (T2DM). A comprehensive search was performed in online major databases up to April 2025 to identify eligible randomized controlled trials (RCTs). Studies meeting the inclusion criteria were systematically reviewed and analyzed for relevant outcomes. A random-effects model was used to calculate pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs), taking into account study heterogeneity. The pooled analysis of 13 RCTs revealed that propolis supplementation in individuals with T2DM led to a significant reduction in fasting plasma glucose (WMD: -15.29 mg/dL), 2-hour postprandial glucose (WMD: -35.41 mg/dL), HbA1c (WMD= -0.58%), fasting insulin (WMD: -1.93 µU/mL), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (WMD: -0.99), low-density lipoprotein cholesterol (LDL-C) (WMD: -11.47 mg/dL), interleukin 6 (IL-6) (WMD: 1.52 pg/mL), tumor necrosis factor-alpha (TNF-α) (WMD: 2.28 pg/mL), and body weight (WMD: 2.09 kg). In contrast, the meta-analysis revealed no significant changes in triglycerides (TG) (p = 0.055), total cholesterol (TC) (p = 0.248), high-density lipoprotein cholesterol (HDL-C) (p = 0.068), and body mass index (BMI) (p = 0.204). Propolis supplementation may serve as a beneficial adjunct therapy for patients with T2DM, showing significant improvements in blood glycemic markers, serum lipid profile, inflammation, and body weight. The overall findings support the use of propolis as a promising complementary approach to enhance cardiometabolic health in T2DM. Not applicable. The online version contains supplementary material available at 10.1007/s40200-025-01682-w.